STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ITCI INTRA CELLULAR THERAPIES INCORPORATED StockScouter® Report

3

StockScouter® Score

INTRA CELLULAR THERAPIES INCORPORATED, a small cap company in the healthcare sector, is expected to slightly underperform the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The multi-period measure of relative price change and consistency is well above average. Positive

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • One or more analysts has modestly decreased quarterly earnings estimates for ITCI. Negative
  • Earnings growth in the past year has decelerated moderately compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be out of favor, stocks will be , and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 100% done.
Progress: 40% done.
Low
High

Core Model Grades

D
C
F
A

Previous Ratings

3
3
4